Relation of Ventricular Tachycardia/Fibrillation to Beta-Blocker Dose Maximization Guided by Pacing Mode Analysis in. Nonpacemaker-Dependent Patients With Implantable Cardioverter-Defibrillator

被引:5
|
作者
Deftereos, Spyridon [1 ]
Giannopoulos, Georgios [1 ]
Kossyvakis, Charalampos [1 ]
Kaoukis, Andreas [1 ]
Raisakis, Konstantinos [1 ]
Panagopoulou, Vasiliki [1 ]
Ntzouvara, Olga [1 ]
Perpinia, Anastasia [1 ]
Rentoukas, Ilias [1 ]
Pyrgakis, Vlasios [1 ]
Manolis, Antonios S. [2 ]
Stefanadis, Christodoulos [3 ]
机构
[1] Athens Gen Hosp G Gennimatas, Dept Cardiol, Athens, Greece
[2] Evaggelismos Hosp, Cardiol Dept 1, Athens, Greece
[3] Univ Athens, Sch Med, Cardiol Dept 1, Hippokrate Hosp, GR-11527 Athens, Greece
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2011年 / 107卷 / 12期
关键词
HEART; SURVIVAL; CARDIOMYOPATHY; PREVENTION; AMIODARONE;
D O I
10.1016/j.amjcard.2011.02.321
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We hypothesized that uptitration of beta blockade and adjustment of pacing parameters to achieve a prevalence of single chamber atrial inhibited rate-responsive (AAIR) pacing in patients with dual-chamber implantable cardioverter-defibrillators (ICDs) would result in maximization of beta-blocker dosage and thus decrease appropriate ICD therapies. We included patients with ischemic or dilated cardiomyopathy and implanted ICDs without contraindications to beta blockers and atrioventricular conduction disturbances. Two 6-month periods were compared: clinically guided phase (pacing function set at back-up dual-chamber rate-responsive pacing mode at a lower rate of about 40 beats/min) and pacing-guided phase, during which beta-blocker dosage was titrated with a target of achieving >90% AAIR pacing (lower rate 60 beats/min). Sixty-one patients (64.2 +/- 8.3 years old) were included. During the pacing-guided phase the target of >= 90% AAIR pacing was achieved in 80.3% of patients. Mean metoprolol dose during the clinically guided phase was 96.7 +/- 29.4 versus 127.0 +/- 39.6 mg/day in the pacing-guided phase (p <0.001). Appropriate ICD therapies were recorded in 35 patients (57.4%) during the clinically guided phase versus 20 (32.8%) during the pacing-guided phase (p <0.001; 1.15 and 0.48 appropriate ICD therapies per patient, respectively, p <0.001). In multivariate analysis, AAIR pacing and beta-blocker dose were inversely related to appropriate ICD therapies. In conclusion, a pacing-guided approach for maximizing beta-blocker doses guided by maximizing AAIR pacing in patients with ICDs may be beneficial compared to the conventional strategy. This pacing-guided approach led to higher daily beta-blocker doses, which were correlated to fewer appropriate ICD therapies. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011; 107:1812-1817)
引用
收藏
页码:1812 / 1817
页数:6
相关论文
共 29 条
  • [1] Relation of ventricular tachycardia/fibrillation to beta-blocker dose maximization guided by pacing mode analysis in non-pacemaker-dependent patients with implantable cardioverter defibrillator
    Deftereos, S.
    Giannopoulos, G.
    Kossyvakis, C.
    Raisakis, K.
    Kaoukis, A.
    Panagopoulou, V.
    Lappos, S.
    Rentoukas, I.
    Pyrgakis, V.
    Stefanadis, C.
    EUROPEAN HEART JOURNAL, 2011, 32 : 308 - 308
  • [2] Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dose-dependent effect
    Jimenez-Candil, Javier
    Hernandez, Jesus
    Martin, Ana
    Ruiz-Olgado, Maria
    Herrero, Jesus
    Ledesma, Claudio
    Morinigo, Jose
    Martin-Luengo, Candido
    EUROPACE, 2010, 12 (09): : 1231 - 1238
  • [3] Right ventricular pacing is an independent predictor for ventricular tachycardia/ventricular fibrillation occurrence and heart failure events in patients with an implantable cardioverter-defibrillator
    Gardiwal, Ajmal
    Yu, Hong
    Oswald, Hanno
    Luesebrink, Ulrich
    Ludwig, Andreas
    Pichlmaier, Andreas Maximilian
    Drexler, Helmut
    Klein, Gunnar
    EUROPACE, 2008, 10 (03): : 356 - 361
  • [4] Beta-blocker therapy is not associated with symptoms of depression and anxiety in patients receiving an implantable cardioverter-defibrillator
    Hoogwegt, Madelein T.
    Kupper, Nina
    Theuns, Dominic A. M. J.
    Jordaens, Luc
    Pedersen, Susanne S.
    EUROPACE, 2012, 14 (01): : 74 - 80
  • [5] TERMINATION AND ACCELERATION OF VENTRICULAR-TACHYCARDIA WITH AUTODECREMENTAL PACING, BURST PACING, AND CARDIOVERSION IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR
    HAMMILL, SC
    PACKER, DL
    STANTON, MS
    FETTER, J
    BARDY, G
    BENDITT, D
    BREITHARDT, G
    CAMM, AJ
    COUMEL, P
    DENDULK, K
    DUBUC, M
    ECHT, D
    HAMMILL, S
    KERR, C
    KLEIN, G
    KUCK, KH
    MILES, W
    PORTERFIELD, J
    RUSKIN, J
    STEINHAUS, D
    TOUBOUL, P
    TROUP, P
    WELLENS, HJJ
    WHEELAN, K
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1995, 18 (01): : 3 - 10
  • [6] Implantable cardioverter-defibrillator therapy in patients with nonischemic ventricular tachycardia or -fibrillation and normal left ventricular function
    Wichter, T
    Block, M
    MartinezRubio, A
    Brunn, J
    Weber, M
    Bansch, D
    Borggrefe, M
    CIRCULATION, 1996, 94 (08) : 763 - 763
  • [7] Noninvasive prediction of fast ventricular tachycardia/ventricular fibrillation in patients with implantable cardioverter-defibrillator: the value of baroreceptor sensitivity
    Flevari, P
    Livanis, EG
    Theodorakis, GN
    Georgiadis, M
    Koutelou, M
    Kastanioti, A
    Mesiskli, T
    Zarvalis, E
    Kremastinos, DTH
    EUROPEAN HEART JOURNAL, 2000, 21 : 553 - 553
  • [8] Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter-defibrillator recipients treated with single beta-blocker or combined amiodarone
    Schupp, Tobias
    Behnes, Michael
    Kim, Seung-hyun
    Mueller, Julian
    Weidner, Kathrin
    Reiser, Linda
    Huseynov, Aydin
    Bollow, Armin
    Borggrefe, Martin
    Taton, Gabriel
    Reichelt, Thomas
    Ellguth, Dominik
    Engelke, Niko
    Akin, Muharrem
    Meininghaus, Dirk Grosse
    Bertsch, Thomas
    Akin, Ibrahim
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 (03) : 493 - 502
  • [9] Efficacy and safety of different antitachycardia pacing sites in the termination of ventricular tachycardia in patients with biventricular implantable cardioverter-defibrillator
    Haghjoo, Majid
    Hajahmadi, Mozhgan
    Fazelifar, Amir Farjam
    Sadr-Ameli, Mohammad Ali
    EUROPACE, 2011, 13 (04): : 509 - 513
  • [10] Does Volume Overload Predict Failed Antitachycardia Pacing Therapy for Ventricular Tachycardia in Patients With an Implantable Cardioverter-Defibrillator?
    Hosseini-khalili, Alireza
    Kluger, Jeffrey
    CIRCULATION, 2014, 130